|
Jun 2
|
With new Enhertu data, an ADC could overtake chemo in breast cancer
|
|
Jun 2
|
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
|
|
May 31
|
The Most Profitable Biotechnology Company in the World
|
|
May 31
|
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
|
|
May 31
|
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
|
|
May 31
|
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
|
|
May 24
|
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
|
|
May 24
|
Here's Why We Think AstraZeneca (LON:AZN) Is Well Worth Watching
|
|
May 23
|
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
|
|
May 23
|
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
|
|
May 23
|
AstraZeneca and Nona Biosciences sign agreement for monoclonal antibody
|
|
May 22
|
Why Astrazeneca (AZN) is a Great Dividend Stock Right Now
|
|
May 22
|
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
|
|
May 22
|
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
|
|
May 22
|
SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca
|
|
May 21
|
AstraZeneca’s $80B sales plan leans on cancer drug expansion
|
|
May 21
|
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
|
|
May 21
|
European Equities Close Lower in Tuesday Trading; AstraZeneca Targets $80 Billion in Revenue by 2030
|
|
May 21
|
AstraZeneca sets sights on $80B in revenue by 2030
|
|
May 21
|
Midday movers: Microsoft, Xpeng rise; Palo Alto, Keysight fall
|